Cargando…

IDO1, FAT10, IFI6, and GILT Are Involved in the Antiretroviral Activity of γ-Interferon and IDO1 Restricts Retrovirus Infection by Autophagy Enhancement

Gamma-interferon (γ-IFN) significantly inhibits infection by replication-defective viral vectors derived from the human immunodeficiency virus type 1 (HIV-1) or murine leukemia virus (MLV) but the underlying mechanism remains unclear. Previously we reported that knockdown of γ-IFN-inducible lysosoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubo, Yoshinao, Yasui, Kiyoshi, Izumida, Mai, Hayashi, Hideki, Matsuyama, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323257/ https://www.ncbi.nlm.nih.gov/pubmed/35883685 http://dx.doi.org/10.3390/cells11142240

Ejemplares similares

Gamma-interferon-inducible, lysosome/endosome-localized thiolreductase, GILT, has anti-retroviral activity and its expression is counteracted by HIV-1
por: Kubo, Yoshinao, et al.
Publicado: (2016)

Efficient viral delivery of Cas9 into human safe harbor
por: Hayashi, Hideki, et al.
Publicado: (2020)

Retrovirus Entry by Endocytosis and Cathepsin Proteases
por: Kubo, Yoshinao, et al.
Publicado: (2012)

Role of Ezrin Phosphorylation in HIV-1 Replication
por: Kamiyama, Haruka, et al.
Publicado: (2018)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Rab3a-Bound CD63 Is Degraded and Rab3a-Free CD63 Is Incorporated into HIV-1 Particles
por: Kubo, Yoshinao, et al.
Publicado: (2017)

Production of Vesicular Stomatitis Virus Glycoprotein-Pseudotyped Lentiviral Vector Is Enhanced by Ezrin Silencing
por: Izumida, Mai, et al.
Publicado: (2020)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

(Acetylacetonato)dibromido[2,2-diphenylhydrazin-1-ido(1−)][2,2-diphenylhydrazin-1-ido(2−)]molybdenum(VI)
por: Bustos, Carlos, et al.
Publicado: (2011)

DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
por: Sailer, Verena, et al.
Publicado: (2019)

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia
por: Chilosi, Marco, et al.
Publicado: (2022)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Identification and optimisation of next generation inhibitors of IDO1 and TDO
por: Wise, Alan, et al.
Publicado: (2015)

Targeting the IDO1 pathway in cancer: from bench to bedside
por: Liu, Ming, et al.
Publicado: (2018)

Cell‐Based Identification of New IDO1 Modulator Chemotypes
por: Hennes, Elisabeth, et al.
Publicado: (2021)

Expression, purification, and kinetic characterization of the human strep-IDO1
por: Saimi, Dilizhatai, et al.
Publicado: (2022)

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Fragments of Target Cells are Internalized into Retroviral Envelope Protein-Expressing Cells during Cell-Cell Fusion by Endocytosis
por: Izumida, Mai, et al.
Publicado: (2016)

Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis
por: Williams, Richard O.
Publicado: (2013)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hfhar53dd7fiquamddv3p7c9mj